In correlation with rather high hormonal receptors expression in uLMS, there is evidence that uLMS shows a good response to aromatase inhibitors as an adjuvant therapy in newly-diagnosed patients with grade I uLMS, as well as those with recurrent, unresectable, and metastatic disease [31,35,36]. The gene discussed is CYP19A1; the disease is metastatic neoplasm.